BioWorld

Nov. 15, 2004

Stock Winners and Losers For The Week

Clinical Trials Update: October 2004

Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: October 2004

FDA Submissions, Approvals And Other Actions: October 2004

BioWorld Stock Report For Public Biotechnology Companies

Medarex's Landmark Deal With BMS: 'What We Set Out To Do'

Industry leaders like to use phrases such as "going forward" and "as the company evolves," even though a troubling number of firms in biotechnology (and other industries) tend instead to stall, slide or die. Read More

Money Raised Year To Date

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...